The Center of Cellular Engineering (CCE) is a comprehensive facility that develops and manufactures a wide range of cell and gene therapies for early phase clinical trials. The CCE is currently manufacturing chimeric antigen receptor (CAR) T-cells, T-cell receptor (TCR)-engineered T-cells, cancer vaccines, induced pluripotent stem cells (iPSC), retinal pigmented epithelial cells derived from autologous iPSC and genetically modified hematopoietic stems cells. In the past the CCE has manufactured dendritic cells, NK cells, virus specific T-cells and mesenchymal stromal cells. The CCE also processes hematopoietic stem cells for transplantation.